ArticleBlood advances2022

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.

Pier Luigi Zinzani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.